Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma

BackgroundFixed airflow obstruction (FAO) is associated with severe eosinophilic asthma. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody for patients with severe, uncontrolled eosinophilic asthma.ObjectiveWe evaluated FAO influence on benralizumab treatment response.MethodsWe performed a post hoc analysis of pooled phase III SIROCCO (NCT01928771) and CALIMA (NCT01914757) data for patients with severe,...